These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 11557686)

  • 1. Intravenous magnesium in experimental stent thrombosis in swine.
    Rukshin V; Azarbal B; Shah PK; Tsang VT; Shechter M; Finkelstein A; Cercek B; Kaul S
    Arterioscler Thromb Vasc Biol; 2001 Sep; 21(9):1544-9. PubMed ID: 11557686
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative antithrombotic effects of magnesium sulfate and the platelet glycoprotein IIb/IIIa inhibitors tirofiban and eptifibatide in a canine model of stent thrombosis.
    Rukshin V; Shah PK; Cercek B; Finkelstein A; Tsang V; Kaul S
    Circulation; 2002 Apr; 105(16):1970-5. PubMed ID: 11997285
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of GP IIb/IIIa receptor monoclonal antibody (7E3), heparin, and aspirin in an ex vivo canine arteriovenous shunt model of stent thrombosis.
    Makkar RR; Litvack F; Eigler NL; Nakamura M; Ivey PA; Forrester JS; Shah PK; Jordan RE; Kaul S
    Circulation; 1997 Feb; 95(4):1015-21. PubMed ID: 9054765
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of acute stent thrombosis under high-shear flow conditions by a nitric oxide donor, DMHD/NO. An ex vivo porcine arteriovenous shunt study.
    Kaul S; Makkar RR; Nakamura M; Litvack FI; Shah PK; Forrester JS; Hutsell TC; Eigler NL
    Circulation; 1996 Nov; 94(9):2228-34. PubMed ID: 8901676
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of GP IIb/IIIa receptor inhibitor tirofiban (aggrastat) in ex vivo canine arteriovenous shunt model of stent thrombosis.
    Rukshin V; Azarbal B; Finkelstein A; Shah PK; Cercek B; Tsang V; Kaul S
    J Cardiovasc Pharmacol; 2003 Apr; 41(4):615-24. PubMed ID: 12658064
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of clopidogrel, aspirin and combined therapy in a porcine ex vivo model of high-shear induced stent thrombosis.
    Makkar RR; Eigler NL; Kaul S; Frimerman A; Nakamura M; Shah PK; Forrester JS; Herbert JM; Litvack F
    Eur Heart J; 1998 Oct; 19(10):1538-46. PubMed ID: 9820993
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Augmentation of in-stent clot dissolution by low frequency ultrasound combined with aspirin and heparin. An ex-vivo canine shunt study.
    Neuman Y; Rukshin V; Tsang V; Atar S; Miyamoto T; Luo H; Kobal S; Thompson T; Birnbaum Y; Horzewski M; Siegel RJ; Kaul S
    Thromb Res; 2003; 112(1-2):99-104. PubMed ID: 15013280
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acute Thrombogenicity of a Durable Polymer Everolimus-Eluting Stent Relative to Contemporary Drug-Eluting Stents With Biodegradable Polymer Coatings Assessed Ex Vivo in a Swine Shunt Model.
    Otsuka F; Cheng Q; Yahagi K; Acampado E; Sheehy A; Yazdani SK; Sakakura K; Euller K; Perkins LEL; Kolodgie FD; Virmani R; Joner M
    JACC Cardiovasc Interv; 2015 Aug; 8(9):1248-1260. PubMed ID: 26292590
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative real-time effects on platelet adhesion and aggregation under flowing conditions of in vivo aspirin, heparin, and monoclonal antibody fragment against glycoprotein IIb-IIIa.
    Turner NA; Moake JL; Kamat SG; Schafer AI; Kleiman NS; Jordan R; McIntire LV
    Circulation; 1995 Mar; 91(5):1354-62. PubMed ID: 7867173
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of a novel platelet nitric oxide donor (LA816), aspirin, clopidogrel, and combined therapy in inhibiting flow- and lesion-dependent thrombosis in the porcine ex vivo model.
    Vilahur G; Segalés E; Salas E; Badimon L
    Circulation; 2004 Sep; 110(12):1686-93. PubMed ID: 15381660
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chimeric 7E3 prevents carotid artery thrombosis in cynomolgus monkeys.
    Rote WE; Nedelman MA; Mu DX; Manley PJ; Weisman H; Cunningham MR; Lucchesi BR
    Stroke; 1994 Jun; 25(6):1223-32; discussion 1233. PubMed ID: 8202985
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does antithrombotic therapy influence residual thrombus after thrombolysis of platelet-rich thrombus? Effects of recombinant hirudin, heparin, or aspirin.
    Mruk JS; Zoldhelyi P; Webster MW; Heras M; Grill DE; Holmes DR; Fuster V; Chesebro JH
    Circulation; 1996 Feb; 93(4):792-9. PubMed ID: 8641009
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blockade of the platelet P2Y12 receptor by AR-C69931MX sustains coronary artery recanalization and improves the myocardial tissue perfusion in a canine thrombosis model.
    Wang K; Zhou X; Zhou Z; Tarakji K; Carneiro M; Penn MS; Murray D; Klein A; Humphries RG; Turner J; Thomas JD; Topol EJ; Lincoff AM
    Arterioscler Thromb Vasc Biol; 2003 Feb; 23(2):357-62. PubMed ID: 12588784
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A thromboxane A2/prostaglandin H2 receptor antagonist (S18886) shows high antithrombotic efficacy in an experimental model of stent-induced thrombosis.
    Vilahur G; Casaní L; Badimon L
    Thromb Haemost; 2007 Sep; 98(3):662-9. PubMed ID: 17849057
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A prospective, nonrandomized, open-labeled pilot study investigating the use of magnesium in patients undergoing nonacute percutaneous coronary intervention with stent implantation.
    Rukshin V; Santos R; Gheorghiu M; Shah PK; Kar S; Padmanabhan S; Azarbal B; Tsang VT; Makkar R; Samuels B; Lepor N; Geft I; Tabak S; Khorsandhi M; Buchbinder N; Eigler N; Cercek B; Hodgson K; Kaul S
    J Cardiovasc Pharmacol Ther; 2003 Sep; 8(3):193-200. PubMed ID: 14506544
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of microsurgical thrombosis by the platelet glycoprotein IIb/IIIa antagonist SR121566A.
    Ching S; Thoma A; Monkman S; Kelton JG
    Plast Reconstr Surg; 2003 Jul; 112(1):177-85. PubMed ID: 12832891
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Porcine model of stent thrombosis: platelets are the primary component of acute stent closure.
    Jeong MH; Owen WG; Staab ME; Srivatsa SS; Sangiorgi G; Stewart M; Holmes DR; Schwartz RS
    Cathet Cardiovasc Diagn; 1996 May; 38(1):38-43. PubMed ID: 8722856
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative study of antithrombotic effect of a low molecular weight heparin and unfractionated heparin in an ex vivo model of deep arterial injury.
    Roqué M; Rauch U; Reis ED; Chesebro JH; Fuster V; Badimon JJ
    Thromb Res; 2000 Jun; 98(6):499-505. PubMed ID: 10899349
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antithrombotic actions of argatroban in rat models of venous, 'mixed' and arterial thrombosis, and its effects on the tail transection bleeding time.
    Berry CN; Girard D; Lochot S; Lecoffre C
    Br J Pharmacol; 1994 Dec; 113(4):1209-14. PubMed ID: 7889274
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antithrombotic and hemostatic capacity of factor Xa versus thrombin inhibitors in models of venous and arteriovenous thrombosis.
    Sinha U; Ku P; Malinowski J; Zhu BY; Scarborough RM; Marlowe CK; Wong PW; Lin PH; Hollenbach SJ
    Eur J Pharmacol; 2000 Apr; 395(1):51-9. PubMed ID: 10781674
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.